Vemlidy
Drug
Gilead Sciences Inc
Total Payments
$20.5M
Transactions
22,683
Doctors
4,586
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.4M | 2,061 | 921 |
| 2023 | $1.4M | 2,099 | 1,084 |
| 2022 | $1.5M | 1,326 | 823 |
| 2021 | $1.6M | 1,301 | 617 |
| 2020 | $1.8M | 1,168 | 559 |
| 2019 | $4.2M | 4,208 | 1,146 |
| 2018 | $3.7M | 3,767 | 1,032 |
| 2017 | $4.9M | 6,753 | 1,513 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.8M | 2,196 | 47.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6.4M | 2,459 | 31.4% |
| Consulting Fee | $2.2M | 852 | 10.7% |
| Food and Beverage | $1.1M | 13,227 | 5.5% |
| Travel and Lodging | $920,790 | 3,618 | 4.5% |
| Education | $2,912 | 330 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $2,500 | 1 | 0.0% |
Payments by Type
General
$10.7M
20,487 transactions
Research
$9.8M
2,196 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children Adolescents with Chronic Hepatitis B Infection | Gilead Sciences, Inc. | $2.2M | 0 |
| Treatment outcomes in chronic hepatitis B patients on sequential therapy with tenofovir alafenamide | Gilead Sciences, Inc. | $1.6M | 0 |
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tenofovir Alafenamide (TAF) versus Tenofovir Disoproxil Fumarate (TDF) in Virologically Suppressed Subjects with Chronic HBV | Gilead Sciences, Inc. | $1.1M | 1 |
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tenofovir Alafenamide (TAF) versus Tenofovir Disoproxil Fumarate (TDF) in Virologically Suppressed Subjects with Chronic HBV | Gilead Sciences Inc | $1.0M | 1 |
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B | Gilead Sciences, Inc. | $657,122 | 3 |
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B | Gilead Sciences, Inc. | $456,176 | 2 |
| Horizontal and Vertical Transmission of Hepatitis B in the DRC: The HOVER-HBV Study | Gilead Sciences, Inc. | $296,912 | 0 |
| Treatment outcomes in chronic hepatitis B patients switched to TAF from entecavir (ETV) | Gilead Sciences, Inc. | $278,978 | 0 |
| A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children Adolescents with Chronic Hepatitis B Infection | Gilead Sciences Inc | $225,078 | 0 |
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B | Gilead Sciences Inc | $220,088 | 2 |
| Hepatitis B-related Complications: Prevalence and Disparities in a US Cohort 2006-2016 | Gilead Sciences, Inc. | $198,437 | 0 |
| Tenofovir Alafenamide for HBV - A Longitudinal Study (TEMUL) | Gilead Sciences Inc | $183,143 | 0 |
| A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Virologically Suppressed Chronic Hepatitis B Subjects with Renal and/or Hepatic Impairment | Gilead Sciences, Inc. | $181,157 | 0 |
| Long-term study to investigate safety and efficacy of TAF in patients with chronic hepatitis B | Gilead Sciences, Inc. | $176,301 | 0 |
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B | Gilead Sciences Inc | $155,240 | 2 |
| HBV Epidemiology | Gilead Sciences, Inc. | $150,000 | 0 |
| Vemlidy Treatment Effectiveness in Treatment-naive, Chronic Hepatitis B Asian Pacific Islanders Adults With Normal ALT and Significant Fibrosis in a Community-Based Clinical Setting | Gilead Sciences, Inc. | $148,725 | 0 |
| Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Cytotoxic Therapy for Solid Tumors | Gilead Sciences, Inc. | $140,400 | 0 |
| A Multi-Center Registry of Patients of African Descent with Chronic Hepatitis B and related outcomes | Gilead Sciences, Inc. | $112,101 | 0 |
| Tenofovir Alafenamide for HBV - A Longitudinal Study (TEMUL) | Gilead Sciences, Inc. | $103,000 | 0 |
Top Doctors Receiving Payments for Vemlidy — Page 5
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Gastroenterology | Saint Clair Shores, MI | $29,453 | 38 |
| , MD | Internal Medicine | Charlotte, NC | $29,395 | 31 |
| , M.D | Gastroenterology | Westminster, CA | $29,388 | 33 |
| , M.D | Gastroenterology | Los Angeles, CA | $28,734 | 28 |
| , MD | Internal Medicine | New York, NY | $28,473 | 34 |
| , D.O | Internal Medicine | Alhambra, CA | $28,076 | 38 |
| , D.O | Internal Medicine | New York, NY | $27,761 | 38 |
| , MD | Gastroenterology | Flushing, NY | $27,727 | 31 |
| , M.D | Gastroenterology | Las Vegas, NV | $26,416 | 32 |
| , M.D | Internal Medicine | Alhambra, CA | $26,223 | 47 |
| , M.D | Hepatology | Baton Rouge, LA | $25,803 | 32 |
| , M.D | Pediatrics | Philadelphia, PA | $25,460 | 10 |
| , MD | Gastroenterology | Columbia, MD | $25,455 | 39 |
| , M.D | Gastroenterology | Seattle, WA | $25,243 | 31 |
| , D.O | Gastroenterology | Hartford, CT | $24,694 | 29 |
| , M.D | Gastroenterology | Arlington Heights, IL | $24,673 | 35 |
| , M.D | Gastroenterology | Bellevue, WA | $24,189 | 42 |
| , M.D | Gastroenterology | Coral Springs, FL | $22,763 | 19 |
| , M.D | Hepatology | Oklahoma City, OK | $22,406 | 24 |
| , M.D | Gastroenterology | Colorado Springs, CO | $22,323 | 31 |
| , MD | Hepatology | Miami, FL | $21,411 | 24 |
| , M.D | Gastroenterology | Hartford, CT | $20,499 | 24 |
| , M.D | Gastroenterology | Bronx, NY | $20,360 | 25 |
| , M.D | Internal Medicine | Alhambra, CA | $20,165 | 29 |
| , M.D | Specialist | West Hollywood, CA | $19,993 | 15 |
Ad
Manufacturing Companies
- Gilead Sciences, Inc. $15.6M
- Gilead Sciences Inc $4.9M
Product Information
- Type Drug
- Total Payments $20.5M
- Total Doctors 4,586
- Transactions 22,683
About Vemlidy
Vemlidy is a drug associated with $20.5M in payments to 4,586 healthcare providers, recorded across 22,683 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences Inc.
Payment data is available from 2017 to 2024. In 2024, $1.4M was paid across 2,061 transactions to 921 doctors.
The most common payment nature for Vemlidy is "Unspecified" ($9.8M, 47.8% of total).
Vemlidy is associated with 20 research studies, including "A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children Adolescents with Chronic Hepatitis B Infection" ($2.2M).